2c:I[856015,["/_next/static/immutable/chunks/1xzisbplk9czp.js","/_next/static/immutable/chunks/3j2i1faptc_-9.js","/_next/static/immutable/chunks/1bqb83_yclja0.js","/_next/static/immutable/chunks/1on664om2hmh1.js","/_next/static/immutable/chunks/30t4sjq-27eg7.js","/_next/static/immutable/chunks/08tq8rmv423j5.js","/_next/static/immutable/chunks/32zk736rs0hqw.js","/_next/static/immutable/chunks/0lbgs964whs_0.js","/_next/static/immutable/chunks/1a_hqhrsle_n_.js","/_next/static/immutable/chunks/0hcnvyarhzl7i.js"],"default"] 2d:T7092,

Summary Table

Category	Details
Risk Factors	Children and adolescents (peak onset 4-6 years and 10-14 years), family history of autoimmune diseases, Northern European descent, presence of other autoimmune conditions (Hashimoto thyroiditis, celiac disease, Addison disease, vitiligo)
Etiology	Autoimmune destruction of pancreatic beta cells mediated by T lymphocytes, associated with HLA-DR3 and HLA-DR4 haplotypes
Patient Presentation	Acute onset of polyuria, polydipsia, polyphagia with weight loss over days to weeks. May present with diabetic ketoacidosis (DKA) as the initial event
Classic Physical Exam	Thin or normal-weight child/adolescent with signs of dehydration, Kussmaul respirations (deep and rapid), fruity breath odor (acetone), altered mental status in severe DKA
Key Diagnostic Results	Random plasma glucose $\geq$ 200 mg/dL with symptoms, fasting glucose $\geq$ 126 mg/dL, HbA1c $\geq$ 6.5%, positive autoantibodies (anti-GAD65, anti-IA-2, anti-insulin, anti-ZnT8), low or absent C-peptide
Management	Lifelong insulin therapy (basal-bolus regimen or insulin pump), blood glucose monitoring, carbohydrate counting, screening for complications and associated autoimmune conditions
Keywords	"Young thin patient," "weight loss despite increased appetite," "fruity breath," "Kussmaul breathing," "DKA at presentation," "autoimmune," "C-peptide low/absent," "anti-GAD antibodies"

1. Pathophysiology

Type 1 Diabetes Mellitus (T1DM) results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans within the pancreas. This process is primarily mediated by autoreactive CD4+ and CD8+ T lymphocytes that infiltrate the pancreatic islets, a histological finding known as insulitis. The autoimmune attack is strongly linked to genetic susceptibility conferred by the HLA class II genes on chromosome 6, particularly the HLA-DR3 and HLA-DR4 haplotypes. Environmental triggers such as viral infections (Coxsackie B virus, enteroviruses) or dietary factors are thought to initiate or accelerate the autoimmune cascade in genetically predisposed individuals, though the exact trigger remains incompletely understood.

The destruction of beta cells is gradual, and clinical symptoms only appear once approximately 80-90% of beta cell mass has been destroyed. This is a critical concept: there is a long preclinical phase during which autoantibodies are detectable but the patient remains euglycemic. Once the remaining beta cells can no longer produce sufficient insulin to maintain glucose homeostasis, the patient crosses the threshold into symptomatic hyperglycemia.

Insulin is an anabolic hormone. Its absence produces a catabolic state that directly explains every symptom. Without insulin, glucose cannot enter insulin-dependent tissues (muscle, adipose), leading to hyperglycemia. When blood glucose exceeds the renal threshold (approximately 180 mg/dL), glucose spills into the urine (glycosuria), pulling water with it via osmotic diuresis, producing polyuria. The resultant volume depletion triggers polydipsia. Because cells are starved of glucose despite its abundance in the blood, the hypothalamus drives hunger, causing polyphagia. Simultaneously, the body breaks down fat and protein for energy, leading to weight loss despite increased caloric intake. This paradox of "starving in the midst of plenty" is the hallmark of T1DM.

When insulin deficiency is severe, unopposed glucagon and counter-regulatory hormones (cortisol, epinephrine, growth hormone) accelerate lipolysis. Free fatty acids flood the liver and undergo beta-oxidation, producing ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone). Accumulation of these organic acids overwhelms the body's buffering capacity, resulting in a high anion gap metabolic acidosis known as diabetic ketoacidosis (DKA). The body compensates with rapid, deep breathing (Kussmaul respirations) to blow off $CO_2$ and reduce acidity. The fruity odor on the breath is from exhaled acetone.

2. Classification and Clinical Manifestation

Classification

Subtype	Mechanism	Autoantibodies	C-Peptide	Typical Onset	Notes
Type 1A (Autoimmune)	T-cell mediated beta cell destruction	Positive (anti-GAD65, anti-IA-2, IAA, anti-ZnT8)	Low/Absent	Children and young adults	Accounts for ~90% of T1DM; associated with other autoimmune diseases
Type 1B (Idiopathic)	Beta cell destruction without identifiable autoimmune markers	Negative	Low/Absent	Variable	More common in African and Asian populations; episodic ketosis-prone course
LADA (Latent Autoimmune Diabetes in Adults)	Slow autoimmune beta cell destruction	Positive (often anti-GAD65 only)	Low but initially preserved	Adults > 30 years	Often misdiagnosed as Type 2 DM initially; progresses to insulin dependence over months to years

By Stage

Stage	Description	Key Features
Stage 1 (Presymptomatic)	Autoimmunity present, normoglycemia	Two or more autoantibodies positive, normal glucose tolerance, no symptoms
Stage 2 (Presymptomatic Dysglycemia)	Autoimmunity with abnormal glucose	Impaired fasting glucose or impaired glucose tolerance, still no classic symptoms
Stage 3 (Symptomatic)	Clinical diabetes	Polyuria, polydipsia, polyphagia, weight loss, possible DKA at onset

DKA Severity Classification

Parameter	Mild	Moderate	Severe
pH	7.25 - 7.30	7.00 - 7.24	< 7.00
Serum Bicarbonate	15 - 18 mEq/L	10 - < 15 mEq/L	< 10 mEq/L
Mental Status	Alert	Alert/Drowsy	Stupor/Coma
Anion Gap	> 10	> 12	> 12

3. Diagnostic Workup

Test	Role	Key Finding
Random Plasma Glucose	Best initial test in symptomatic patient	$\geq$ 200 mg/dL with classic symptoms confirms diagnosis
Fasting Plasma Glucose	Confirmatory (if asymptomatic)	$\geq$ 126 mg/dL on two occasions
HbA1c	Reflects 2-3 month average glucose	$\geq$ 6.5%
Oral Glucose Tolerance Test (OGTT)	Confirmatory	2-hour glucose $\geq$ 200 mg/dL
Autoantibodies	Distinguish T1DM from T2DM	Anti-GAD65, anti-IA-2, IAA, anti-ZnT8
C-Peptide	Assess residual beta cell function	Low or undetectable in T1DM
Basic Metabolic Panel	Evaluate for DKA	Elevated anion gap, low bicarbonate, elevated potassium (initially)
Urinalysis	Screen for ketones	Ketonuria, glycosuria
Serum Beta-Hydroxybutyrate	Most accurate ketone measurement	Elevated in DKA

In a classic exam vignette, a young, thin patient presenting with polyuria, polydipsia, weight loss, and a blood glucose of 350 mg/dL, the diagnosis is essentially clinical. A random plasma glucose $\geq$ 200 mg/dL in the presence of classic hyperglycemic symptoms is sufficient to diagnose diabetes in a single visit without repeat testing. This is the best initial diagnostic step when the presentation is acute and symptomatic.

When the presentation is ambiguous or the patient is asymptomatic, confirmation requires two abnormal results from the same or different tests (fasting glucose $\geq$ 126 mg/dL, HbA1c $\geq$ 6.5%, or OGTT 2-hour value $\geq$ 200 mg/dL) on separate occasions.

Once diabetes is confirmed, the next question on the exam is often: "Is this Type 1 or Type 2?" This is where autoantibodies and C-peptide become essential. Anti-GAD65 antibodies are the most commonly tested and the most sensitive single marker for T1DM autoimmunity. A positive result, combined with a low or undetectable C-peptide level (reflecting absent endogenous insulin production), confirms the diagnosis as Type 1. C-peptide is produced in equimolar amounts with insulin during proinsulin cleavage, so it serves as a reliable surrogate for endogenous insulin secretion that is not confounded by exogenous insulin administration.

In a patient presenting with DKA, the workup priorities shift to acute assessment. You must obtain: arterial blood gas (to confirm metabolic acidosis), basic metabolic panel (to calculate anion gap and check potassium), serum beta-hydroxybutyrate (preferred over urine ketones for accuracy), complete blood count, and urinalysis. The anion gap is calculated as:

$$Anion\ Gap = Na^+ - (Cl^- + HCO_3^-)$$

A normal anion gap is 8-12 mEq/L. In DKA, it is characteristically elevated due to accumulation of ketoacid anions.

A critical exam pearl: serum potassium may be initially normal or elevated in DKA despite total body potassium depletion. This is because acidosis and insulin deficiency both drive potassium out of cells into the extracellular space. Once insulin therapy begins and acidosis corrects, potassium shifts back intracellularly, and hypokalemia may become life-threatening if not anticipated and replaced.

4. Management and Treatment

Setting	Intervention	Details
DKA: Fluid Resuscitation	IV Normal Saline (0.9% NaCl)	Initial bolus 15-20 mL/kg/hr for the first hour, then 250-500 mL/hr adjusted to clinical status
DKA: Insulin	Regular insulin IV drip	0.1 units/kg/hr continuous infusion (do NOT bolus in pediatric patients); hold if $K^+$ < 3.3 mEq/L
DKA: Potassium	IV KCl replacement	If $K^+$ < 3.3: hold insulin, replace $K^+$ first. If 3.3-5.3: add 20-40 mEq/L to IV fluids. If > 5.3: recheck in 2 hours
DKA: Bicarbonate	IV Sodium Bicarbonate	Only if pH < 6.9 (100 mmol in 400 mL water with 20 mEq KCl over 2 hours)
DKA: Dextrose	Add D5 to IV fluids	When glucose falls to $\leq$ 200 mg/dL, add dextrose to prevent hypoglycemia while continuing insulin to clear ketones
Chronic: Basal Insulin	Long-acting insulin (Glargine or Detemir)	Once or twice daily; provides baseline coverage
Chronic: Bolus Insulin	Rapid-acting insulin (Lispro, Aspart, Glulisine)	Before each meal, dosed by carbohydrate counting and correction factor
Chronic: Monitoring	Self-monitoring of blood glucose or continuous glucose monitor (CGM)	Target pre-meal glucose 80-130 mg/dL, post-meal < 180 mg/dL, HbA1c < 7%
Chronic: Screening	Complication and autoimmune screening	Annual retinal exam (start 5 years after diagnosis or at puberty), annual urine albumin-to-creatinine ratio, thyroid function tests, celiac screening

DKA Protocol

The management of DKA follows a strict, testable sequence: fluids first, then potassium assessment, then insulin.

Step 1: Aggressive IV fluid resuscitation with isotonic saline is the absolute first priority. Patients in DKA are profoundly volume-depleted (often 5-10% of body weight). Fluid replacement alone will begin to lower glucose by improving renal perfusion and glucosuria. Administer 0.9% NaCl at 15-20 mL/kg/hour for the first hour.

Step 2: Check serum potassium before starting insulin. This is one of the most commonly tested decision points. If potassium is below 3.3 mEq/L, insulin must be withheld and potassium aggressively replaced, because insulin will drive potassium further into cells and can precipitate fatal cardiac arrhythmias. If potassium is 3.3-5.3 mEq/L, add 20-40 mEq of KCl per liter of IV fluids and start insulin simultaneously. If potassium is above 5.3 mEq/L, start insulin and recheck potassium every 2 hours.

Step 3: Begin continuous IV regular insulin infusion at 0.1 units/kg/hour. The goal is a glucose reduction of 50-70 mg/dL per hour. When blood glucose drops to approximately 200 mg/dL, add dextrose (D5) to the IV fluids but continue the insulin drip. This is a frequently tested concept: you do not stop insulin when glucose normalizes because the goal of insulin in DKA is not merely to lower glucose but to suppress ketogenesis and close the anion gap. Stopping insulin prematurely will cause rebound ketoacidosis.

Transition to subcutaneous insulin occurs when the patient is eating, the anion gap has closed, pH is above 7.3, and bicarbonate is above 18 mEq/L. Overlap subcutaneous basal insulin with the IV drip for 1-2 hours before discontinuing the drip to prevent a gap in insulin coverage.

Basal-Bolus Regimen

All patients with T1DM require lifelong exogenous insulin. The standard regimen is basal-bolus therapy, which physiologically mimics normal insulin secretion:

Basal insulin (insulin glargine, given once daily, or insulin detemir, given once or twice daily) provides a steady background level of insulin over 24 hours, suppressing hepatic glucose output between meals and overnight. The total daily dose of insulin is typically estimated at 0.4-1.0 units/kg/day, with roughly 40-50% given as basal and 50-60% divided among pre-meal boluses.

Bolus insulin (rapid-acting: lispro, aspart, or glulisine) is administered 10-15 minutes before meals. The dose is calculated using two components: an insulin-to-carbohydrate ratio (e.g., 1 unit per 10-15 grams of carbohydrate) and a correction factor (e.g., 1 unit for every 50 mg/dL above target). Both ratios are individualized.

An alternative to multiple daily injections is a continuous subcutaneous insulin infusion (CSII) pump, which delivers rapid-acting insulin as both a continuous basal rate and patient-activated boluses.

HbA1c should be measured every 3 months, with a target of < 7% for most adults and an individualized target for children (often < 7.5%).

Screening for Complications

Because T1DM carries long-term microvascular and macrovascular risks, structured screening is essential. Diabetic retinopathy screening begins 5 years after diagnosis (or at the onset of puberty, whichever comes first) with annual dilated fundoscopic exams. Diabetic nephropathy screening begins at the same interval with annual urine albumin-to-creatinine ratio. If microalbuminuria is detected, first-line treatment is an ACE inhibitor or ARB, even in normotensive patients, due to the renoprotective effect. Patients should also be screened for thyroid disease (TSH) and celiac disease (tissue transglutaminase IgA antibodies) at diagnosis and periodically thereafter, given the high rates of autoimmune comorbidity.

5. Differential Diagnosis and Distractors

Differential	Why It Looks Similar	Key Discriminator
Type 2 Diabetes Mellitus	Both present with hyperglycemia, polyuria, polydipsia	T2DM: overweight/obese patient, older onset, acanthosis nigricans, high C-peptide, negative autoantibodies, rarely presents with DKA (though it can in ketosis-prone T2DM)
MODY (Maturity Onset Diabetes of the Young)	Young patient with diabetes, may be non-obese	MODY: strong family history across 3+ generations (autosomal dominant), negative autoantibodies, mild hyperglycemia, often incidental finding, no ketosis
Secondary Diabetes (Cystic Fibrosis-Related)	Young patient with new-onset diabetes	History of CF, pancreatic exocrine insufficiency, progressive insulin deficiency but not autoimmune
DKA vs. Alcoholic Ketoacidosis	Both present with anion gap metabolic acidosis and ketones	Alcoholic ketoacidosis: history of chronic alcohol use, recent binge followed by poor intake, glucose is normal or low (not elevated), beta-hydroxybutyrate predominates
DKA vs. Hyperosmolar Hyperglycemic State (HHS)	Both are diabetic emergencies with severe hyperglycemia	HHS: more common in T2DM, glucose often > 600 mg/dL, serum osmolality > 320 mOsm/kg, no significant ketosis or acidosis, profound dehydration, altered mental status
Diabetes Insipidus	Presents with polyuria and polydipsia	Blood glucose is normal, urine is dilute (low osmolality), no glycosuria, caused by ADH deficiency (central) or resistance (nephrogenic)
Psychogenic Polydipsia	Polydipsia and polyuria	Normal blood glucose, dilutional hyponatremia, water deprivation test shows appropriate urine concentration

6. Traps and High-Yield Pearls

The most common way students lose points on T1DM questions is by mismanaging the potassium in DKA. The classic trap: a patient presents with DKA, labs show a glucose of 500 mg/dL and a potassium of 3.0 mEq/L, and the question asks for the "next best step." The instinct is to start insulin, but the correct answer is to replace potassium first and withhold insulin. Administering insulin to a hypokalemic patient can cause fatal hypokalemia and cardiac arrest. This concept is tested repeatedly because it reverses the intuitive reflex to treat the hyperglycemia immediately.

A second common trap involves the transition point in DKA management. When glucose reaches 200 mg/dL, students frequently select "discontinue insulin drip" as the answer. The correct answer is to add dextrose to the IV fluids and continue the insulin infusion. The purpose of insulin in DKA is to halt ketogenesis. Stopping it prematurely will cause the anion gap to reopen even as glucose appears controlled.

Third, students often confuse T1DM with T2DM in atypical presentations. An overweight adolescent with acanthosis nigricans and new-onset diabetes is T2DM until proven otherwise, even though T1DM is "the diabetes of the young." Conversely, an adult over 30 presenting with what looks like T2DM but who is thin and poorly controlled on metformin should raise suspicion for LADA, and autoantibodies (especially anti-GAD65) should be checked.

Finally, remember that HbA1c can be falsely low or high depending on red blood cell turnover. Conditions that increase RBC turnover (hemolytic anemia, sickle cell disease, recent blood loss or transfusion) will falsely lower HbA1c, while conditions that decrease turnover (iron deficiency anemia, splenectomy) will falsely elevate it. This is tested as a reasoning question: "Why does this patient's HbA1c not match their home glucose readings?"

The core competency being tested across T1DM questions is the ability to recognize the autoimmune, insulin-deficient nature of the disease, to distinguish it from Type 2 and other forms of diabetes, and to execute the DKA management algorithm in the correct sequence with attention to potassium handling and the rationale for continuing insulin beyond glucose normalization.

1d:["$","$L2c",null,{"article":{"id":"7946d343-cbc0-47fc-b9a8-bac91651bcb9","title":"Diabetes Melitus Tipe 1","content":"$2d","category":"Endokrin-Metabolik","created_at":"2026-09-05T10:41:36.338519+00:00","status":"published","subcategory":null},"questionCount":0,"sections":[{"id":"section-pathophysiology","num":"01","title":"Pathophysiology"},{"id":"section-classification-and-clinical-manifestation","num":"02","title":"Classification and Clinical Manifestation"},{"id":"section-diagnostic-workup","num":"03","title":"Diagnostic Workup"},{"id":"section-management-and-treatment","num":"04","title":"Management and Treatment"},{"id":"section-differential-diagnosis-and-distractors","num":"05","title":"Differential Diagnosis and Distractors"},{"id":"section-traps-and-high-yield-pearls","num":"06","title":"Traps and High-Yield Pearls"}],"hasSummaryTable":true}]